Endemic fungal infections in inflammatory bowel disease associated with anti-tnf antibody therapy

Inflammatory Bowel Diseases

Volumn 19, Issue 11, 2013, Pages 2490-2500

  Ordonez, Miguel E ^a   Farraye, Francis A ^b   Palma, Jack A Di ^a  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adalimumab; Blastomycosis; Certolizumab pegol; Coccidioidomycosis; Crohn's disease; Endemic fungi; Fungal infections; Histoplasmosis; Inflammatory bowel disease; Infliximab; TNF inhibitors; Tumor necrosis factor alpha antagonists; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CERTOLIZUMAB PEGOL; ETANERCEPT; FLUCONAZOLE; INFLIXIMAB; ITRACONAZOLE; KETOCONAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADVERSE OUTCOME; BLASTOMYCES DERMATITIDIS; BLASTOMYCOSIS; CLINICAL PRACTICE; COCCIDIOIDOMYCOSIS; CONGESTIVE HEART FAILURE; CROHN DISEASE; CYTOKINE PRODUCTION; DIABETIC PATIENT; DISEASE COURSE; DRUG APPROVAL; DRUG SURVEILLANCE PROGRAM; ENDEMIC DISEASE; ENDEMIC SPECIES; ENTERITIS; FOOD AND DRUG ADMINISTRATION; HEMATOLOGIC DISEASE; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INFECTION; INFECTION RISK; INFECTIOUS COMPLICATION; INJECTION SITE REACTION; LIVER FUNCTION TEST; LYMPHADENITIS; MEDIASTINUM LYMPH NODE; META ANALYSIS (TOPIC); MONOTHERAPY; MYCOBACTERIOSIS; MYCOSIS; OPPORTUNISTIC INFECTION; ORGAN TRANSPLANTATION; PATIENT EDUCATION; PATIENT MONITORING; PERICARDITIS; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; TRAVEL; TREATMENT INDICATION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ENDEMIC DISEASES; HUMANS; INFLAMMATORY BOWEL DISEASES; MYCOSES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84888230400     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e31828f1fba     Document Type: Review

References (137)

1. Parkes M. Evidence from genetics for a role of autophagy and innate immunity in IBD pathogenesis. Dig Dis. 2012;30:330-333.
2. Scarpa M, Stylianou E. Epigenetics: concepts and relevance to IBD pathogenesis. Inflamm Bowel Dis. 2012;18:1982-1996.
3. Winther KV, Jess T, Langholz E, et al. Survival and cause specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. Gastroenterology. 2003;125:1576-1582.
4. Jess T, Winther KV, Munkholm P, et al. Mortality and causes of death in Crohns disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Gastroenterology. 2002;122:1808-1814.
5. Aberra FN, Lichtenstein GR. Methods to avoid infections in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:685-695.
6. Mylonaki M, Langmead L, Pantes A. Enteric infection in relapse of inflammatory bowel disease: Importance of microbiological examination of stool. Eur J Gastroenterol Hepatol. 2004;16:775-778.
7. Hurst RD, Molinari M, Chung TP, et al. Prospective study of the features, indications, and surgical treatment in 513 consecutive patients affected by Crohns disease. Surgery. 1997;122:661-668.
8. Kotanagi H, Sone S, Fukuoka T, et al. Liver abscess as the initial manifestation of colonic Crohns disease: report of a case. Jpn J Surg. 1991; 21:348-351.
9. Ben-Ami H, Ginesin Y, Behar DM, et al. Diagnosis and treatment of urinary tract complications in Crohns disease: An experience over 15 years. Can J Gastroenterol. 2002;16:225-229.
10. Siegel CA. Review article: explaining risks of inflammatory bowel disease therapy to patients. Aliment Pharmacol Ther. 2011;33:23-32.
11. Siegel CA, Hur C, Korzenik JR, et al. Risks and benefits of infliximab for the treatment of Crohns disease. Clin Gastroenterol Hepatol. 2006; 4:1017-1024.
12. Wallis RS, Broder MS, Wong JY. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004; 38:1261-1265.
13. Toruner M, Loftus EV Jr, Scott W, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929-936.
14. Bachmann F, Nast A, Sterry W, et al. Safety and efficacy of the tumor necrosis factor antagonists. Semin Cutan Med Surg. 2010;29:35-47.
15. Smith JA. Tumor necrosis factor inhibitors and fungal infections. Curr Fungal Infect Rep. 2010;4:38-45.
16. Infliximab (Remicade) [package insert]. Horsham, PA: Centocor, Inc; 2007.
17. Adalimumab (Humira) [package insert]. Abbott Park, IL: Abbott Laboratories; 2007.
18. Certolizumab (Cimzia) [package insert]. Smyrna, GA: UCB, Inc; 2009.
19. Hyrich KL. Assessing the safety of biologic therapies in rheumatoid arthritis: the challenges of study design. J Rheumatol. 2005;32(suppl 72):48-50.
20. Barbara Segal B, Nelson A, Rhodus L, et al. Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;106:778-787.
21. Gartlehner G, Hansen RA, Jonas BL, et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: A systematic review and metaanalysis. J Rheumatol. 2006;33:2398-2408.
22. Sarzi-Puttini P, Atzeni F, Shoenfeld Y, et al. TNF-alpha, rheumatoid arthritis, and heart failure: A rheumatological dilemma. Autoimmun Rev. 2005;153-161.
23. Setoguchi S, Solomon DH, Weinblatt ME, et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:2757-2764.
24. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy. Arthritis Rheum. 2007;56:2886-2895.
25. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohns disease. N Engl J Med. 2004;350:876-885.
26. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohns disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-1549.
27. Dunlop H. Infliximab (Remicade) and etanercept (Enbrel): serious infections and tuberculosis. Can Med Assoc J. 2004;171:992-993.
28. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohns disease: the Mayo Clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.
29. Baeten D, Kruithof E, van den Bosch F, et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: A new perspective on the role of host defense in the pathogenesis of the disease Ann Rheum Dis. 2003;62:829-834.
30. Tsiodras S, Samonis G, Boumpas DT, et al. Fungal infections complicating tumor necrosis factor a blockade therapy. Mayo Clin Proc. 2008; 83:181-194.
31. Burmester GR, Mariette X, Montecucco C, et al; Research in Active Rheumatoid Arthritis Study Group. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis. 2007;66:732-739.
32. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52: 3403-3412.
33. Keystone EC, Kavanaugh AF, Sharp JT. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50:1400-1411.
34. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. Arthritis Rheum. 2004;50:3432-3443.
35. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-2285.
36. Afif W, Loftus EV Jr. Safety profile of IBD therapeutics: Infectious risks. Med Clin N Am. 2010;94:115-133.
37. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54:2368-2376.
38. Rahier JF, Yazdanpanah Y, Colombel JF, et al. The European (ECCO) consensus on infection in IBD: what does it change for the clinician Gut. 2009:58;1313-1315.
39. Lees CW, Ali AI, Thompson AI, et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: Analysis of 620 patient-years follow-up. Aliment Pharmacol Ther. 2009;29:286-297.
40. Colombel JF, Sandborn WJ, Panaccione R, et al. Adalimumab safety in global clinical trials of patients with Crohns disease. Inflamm Bowel Dis. 2009;15:1308-1319.
41. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohns disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-630.
42. Lichtenstein GR, Cohen R, Feagan B, et al. Safety of infliximab and other Crohns disease therapies: TREAT registry data with nearly 24,575 patient years of followup. Am J Gastroenterol. 2008;104(suppl 1):5436.
43. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: A single-centre cohort study. Gut. 2009;58:501-508.
44. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut. 2004;53:849-853.
45. Schneeweiss S, Korzenik J, Solomon DH, et al. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther. 2009;30:253-264.
46. Filler SG, Yeaman MR, Sheppard DC. Tumor necrosis factor inhibition and invasive fungal infections. Clin Infect Dis. 2005;41(suppl 3):S208-S212.
47. Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis An update on safety. J Rheumatol. 2002;29(suppl 65):33-38.
48. Allendoerfer R, Deepe GS Jr. Regulation of infection with Histoplasma capsulatum by TNFR1 and-2. J Immunol. 2000;165:2657-2664.
49. Djeu JY, Blanchard DK, Halkias D, et al. Growth inhibition of Candida albicans by human polymorphonuclear neutrophils: Activation by interferona and tumor necrosis factor. J Immunol. 1986;137:2980-2984.
50. Bekker LG, Freeman S, Murray PJ, et al. TNF-a controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways. J Immunol. 2001;166:6728-6734.
51. Beaman L. Effects of recombinant gamma interferon and tumor necrosis factor on in vitro interactions of human mononuclear phagocytes with Coccidioides immitis. Infect Immun. 1991;59:4227-4229.
52. Crum NF, Lederman ER, Wallace MR. Infections associated with tumor necrosis factor-a antagonists. Medicine. 2005;84:291-302.
53. Lugering A, Schmidt M, Lugering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohns disease by using a caspase-dependent pathway. Gastroenterology. 2001;121:1145-1157.
54. Doran MF, Crowson CS, Pond GR. Frequency of infection in patients with rheumatoid arthritis compared with controls: A population based study. Arthritis Rheum. 2002;46:2287-2293.
55. Wood KL, Hage CA, Knox KS. Histoplasmosis after treatment with antitumor necrosis factor-a therapy. Am J Respir Crit Care Med. 2003;167: 1279-1282.
56. Vail GM, Young RS, Wheat LJ, et al. Incidence of histoplasmosis following allogeneic bone marrow transplant or solid organ transplant in a hyperendemic area. Transpl Infect Dis. 2002;4:148-151.
57. Lee JH, Slifman NR, Gershon SK. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor a antagonists infliximab and etanercept. Arthritis Rheum. 2002;46:2565-2570.
58. Winthrop KL, Yamashita S, Beekman SE, et al. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network. Clin Infect Dis. 2008;46:1738-1740.
59. Wheat J, Sarosi G, McKinsey D, et al. Practice guidelines for the management of patients with histoplasmosis. Clin Infect Dis. 2000;30:688-695.
60. McKinsey DS, McKinsey JP, Brune PR. Diagnosis and management of histoplasmosis. Curr Fungal Infect Rep. 2008;2:94-102.
61. Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Disease Society of America. Clin Infect Dis. 2007;45:807-825.
62. Wheat LJ, Conces D, Allen SD, et al. Pulmonary histoplasmosis syndromes: recognition, diagnosis, and management. Semin Respir Crit Care Med. 2004;25:129-144.
63. Hage CA, Bowyer S, Tarvin SE, et al. Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy. Clin Infect Dis. 2010;50:85-92.
64. Hage CA, Davis TE, Egan L, et al. Diagnosis of pulmonary histoplasmosis and blastomycosis by detection of antigen in bronchoalveolar lavage fluid using an improved second-generation enzyme-linked immunoassay. Respir Med. 2007;101:43-47.
65. Wheat LJ. Nonculture diagnostic methods for invasive fungal infections. Curr Infect Dis Rep. 2007;9:465-471.
66. Wheat LJ. Improvements in diagnosis of histoplasmosis. Expert Opin Biol Ther. 2006;6:1207-1221.
67. Wheat LJ, Wheat H, Connolly P, et al. Cross-reactivity in Histoplasma capsulatum variety capsulatum antigen assays in urine samples from patients with endemic mycoses. Clin Infect Dis. 1997;24:1169-1171.
68. Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis. 2005;40(suppl 6):S401-S408.
69. Wheat LJ, Connolly P, Smedema M, et al. Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome. Clin Infect Dis. 2001;33:1910-1913.
70. Wheat LJ, Connolly P, Smedema M, et al. Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole. J Antimicrob Chemother. 2006;57:1235-1239.
71. Wheat J, Hafner R, Korzun AH. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. Am J Med. 1995;98:336-342.
72. Wheat LJ, Connolly P, Haddad N, et al. Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. Antimicrob Agents Chemother. 2002;46: 248-250.
73. Savides TJ, Gress FG, Wheat LJ, et al. Dysphagia due to mediastinal granulomas: diagnosis with endoscopic ultrasonography. Gastroenterology. 1995;109:366-373.
74. Maholtz MS, Dauber JH, Yousem SA. Fluconazole therapy in Histoplasma mediastinal granuloma. Am J Med Sci. 1994;307:274-277.
75. Davis AM, Pierson RN, Loyd JE. Mediastinal fibrosis. Semin Respir Infect. 2001;16:119-130.
76. McKinsey DS, Wheat LJ, Cloud GA, et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis. 1999;28:1049-1056.
77. Wallis RS, Broder M, Wong J, et al. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis. 2005;41:S194-S198.
78. Sawalha AH, Lutz BD, Chaudhary NA, et al. Panniculitis: A presenting manifestation of disseminated histoplasmosis in a patient with rheumatoid arthritis. J Clin Rheumatol. 2003;9:259-262.
79. Galandiuk S, Davis BR. Infliximab-induced disseminated histoplasmosis in a patient with Crohns disease. Nat Clin Pract Gastroenterol Hepatol. 2008;5:283-287.
80. Nakelchik M, Mangino JE. Reactivation of histoplasmosis after treatment with infliximab. Am J Med. 2002;112:78-79.
81. Jain VV, Evans T, Peterson MW. Reactivation histoplasmosis after treatment with anti-tumor necrosis factor-a in a patient from a nonendemic area. Respir Med. 2006;100:1291-1293.
82. Ankobiah WA, Vaidya K, Powell S, et al. Disseminated histoplasmosis in AIDS. Clinicopathologic features in seven patients from a nonendemic area. N Y State J Med. 1990;90:234-238.
83. Hughes WT. Hematogenous histoplasmosis in the immunocompromised child. J Pediatr. 1984;105:569-575.
84. Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:1801-1812.
85. Dworkin MS, Duckro AN, Proia L, et al. The epidemiology of blastomycosis in Illinois and factors associated with death. Clin Infect Dis. 2005;41:e107-e111.
86. Cano MV, Ponce-de-Leon GF, Tippen S, et al. Blastomycosis in Missouri: epidemiology and risk factors for endemic disease. Epidemiol Infect. 2003;131:907-914.
87. McKinnell JA, Pappas PG. Blastomycosis: new insights into diagnosis, prevention, and treatment. Clin Chest Med. 2009;30:227-239.
88. Chapman SW, Bradsher RW, Campbell GD, et al. Practice Guidelines for the Management of Patients with Blastomycosis. Clin Infect Dis. 2000;30:679-683.
89. Klein BS, Vergeront JM, Weeks RJ. Isolation of Blastomyces dermatitidis in soil associated with a large outbreak of blastomycosis in Wisconsin. N Engl J Med. 1986;314:529-534.
90. Lemos LB, Baliga M, Guo M. Acute respiratory distress syndrome and blastomycosis: presentation of nine cases and review of the literature. Ann Diagn Pathol. 2001;5:1-9.
91. Crampton TL, Light RB, Berg GM, et al. Epidemiology and clinical spectrum of blastomycosis diagnosed at Manitoba hospitals. Clin Infect Dis. 2002;34:1310-1316.
92. Chapman SW, Lin AC, Hendricks KA, et al. Endemic blastomycosis in Mississippi: epidemiological and clinical studies. Semin Respir Infect. 1997 12:219-228.
93. Linden P, Williams P, Chan KM. Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections. Clin Transplant. 2000;14:329-339.
94. Walker K, Skelton H, Smith K. Cutaneous lesions showing giant yeast forms of Blastomyces dermatitidis. J Cutan Pathol. 2002;29:616-618.
95. Martynowicz MA, Prakash UB. Pulmonary blastomycosis: An appraisal of diagnostic techniques. Chest. 2002; 121:768-773.
96. Durkin M, Witt J, Lemonte A, et al. Antigen assay with the potential to aid in diagnosis of blastomycosis. J Clin Microbiol. 2004;42:4873-4875.
97. Spector D, Legendre AM, Wheat J, et al. Antigen and antibody testing for the diagnosis of blastomycosis in dogs. J Vet Intern Med. 2008;22: 839-843.
98. Dismukes WE, Bradsher RW Jr, Cloud GC. Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group. Am J Med. 1992;93:489-497.
99. Bradsher RW Jr. Pulmonary blastomycosis. Semin Respir Crit Care Med. 2008;29:174-181.
100. Friedman JA, Wijdicks EF, Fulgham JR, et al. Meningoencephalitis due to Blastomyces dermatitidis: case report and literature review. Mayo Clin Proc. 2000;75:403-408.
101. Pappas PG, Pottage JC, Powderly WG, et al. Blastomycosis in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1992; 116:847-853.
102. Gauthier GM, Safdar N, Klein BS, et al. Blastomycosis in solid organ transplant recipients. Transpl Infect Dis. 2007;9:310-317.
103. Panicker J, Walsh T, Kamani N. Recurrent central nervous system blastomycosis in an immunocompetent child treated successfully with sequential liposomal amphotericin B and voriconazole. Pediatr Infect Dis J. 2006;25:377-379.
104. Bakleh M, Aksamit AJ, Tleyjeh IM, et al. Successful treatment of cerebral blastomycosis with voriconazole. Clin Infect Dis. 2005;40:e69-e71.
105. Serody JS, Mill MR, Detterbeck FC, et al. Blastomycosis in transplant recipients: report of a case and review. Clin Infect Dis. 1993;16:54-58.
106. Goldman M, Zackin R, Fichtenbaum CJ, et al. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clin Infect Dis. 2004;38:1485-1489.
107. Pappas PG, Threlkeld MG, Bedsole GD, et al. Blastomycosis in immunocompromised patients. Medicine. 1993;72:311-325.
108. Pappas PG. Blastomycosis in immunocompromised patients. Semin Respir Infect. 1997;12:243-251.
109. Food and Drug Administration Alert September 2008: Information for Healthcare Professionals: Cimzia (certolizumab pegol), Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab). Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm124185.htm. Accessed September 1, 2012.
110. Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. Clin Infect Dis. 2005;41:1217-1223.
111. Galgiani JN, Ampel NM, Blair JE, et al. Practice guidelines for the treatment of coccidioidomycosis. Clin Infect Dis. 2000;30:658-661.
112. Galgiani JN. Coccidioidomycosis: A regional disease of national importance-rethinking approaches for control. Ann Intern Med. 1999;130:293-300.
113. Panackal AA, Hajjeh RA, Cetron MS, et al. Fungal infections among returning travelers. Clin Infect Dis. 2002;35:1088-1095.
114. Feldman BS, Snyder LS. Primary pulmonary coccidioidomycosis. Semin Respir Infect. 2001;16:231-237.
115. Pappagianis D. Serologic studies in coccidioidomycosis. Semin Respir Infect. 2001;16:242-250.
116. Blair JE, Logan JL. Coccidioidomycosis in solid organ transplantation. Clin Infect Dis. 2001;33:1536-1544.
117. Vikram HR, Dosanjh A, Blair JE. Coccidioidomycosis and lung transplantation. Transplantation. 2011;92:171-121.
118. Vucicevic D, Carey EJ, Blair JE. Coccidioidomycosis in liver transplant recipients in an endemic area. Am J Transplant. 2011;11:111-119.
119. Braddy CM, Heilman RL, Blair JE. Coccidioidomycosis after renal transplantation in an endemic area. Am J Transplant. 2006;6:340.
120. Cha JM, Jung S, Bahng HS, et al. Multi-organ failure caused by reactivated coccidioidomycosis without dissemination in a patient with renal transplantation. Respirology. 2000;5:87.
121. Keckich DW, Blair JE, Vikram HR, et al. Reactivation of coccidioidomycosis despite antifungal prophylaxis in solid organ transplant recipients. Transplantation. 2011;92:88-93.
122. Blair JE, Douglas DD, Mulligan DC. Early results of targeted prophylaxis for coccidioidomycosis in patients undergoing orthotopic liver transplantation within an endemic area. Transpl Infect Dis. 2003; 5:3-8.
123. Blair JE, Kusne S, Carey EJ, et al. The prevention of recrudescent coccidioidomycosis after solid organ transplantation. Transplantation. 2007;83:1182.
124. Bergstrom L, Yocum DE, Ampel NM, et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum. 2004;50:1959-1966.
125. Afif W, Loftus EV. Safety profile of IBD therapeutics: Infectious risks. Gastroenterol Clin N Am. 2009;38:691-709.
126. U.S. Food and Drug Administration, Center for Drug Evaluation and Research Arthritis Advisory Committee. Remicade (Infliximab), Efficacy and Safety Review Briefing Document. March 4, 2003. Available at: http://www.fda.gov/OHRMS/DOCKETS/ac/03/transcripts/3930T1.pdf. Accessed September 1, 2012.
127. Maini RN, Breedveld FC, Kalden JR, et al; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 2004;50:1051-1065.
128. Mertz L, Blair J. Coccidioidomycosis in rheumatology patients: Incidence and potential risk factors. Ann N Y Acad Sci. 2007;1111:343-357.
129. Dweik M, Baethge BA, Duarte AG. Coccidioidomycosis pneumonia in a nonendemic area associated with infliximab. South Med J. 2007;100: 517-518.
130. Narayana N, Gifford R, Giannini P, et al. Oral histoplasmosis: An unusual presentation. Head Neck. 2009;31:274-277.
131. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol. 2006;2:602-610.
132. McKinsey DS, Spiegel RA, Hutwagner L. Prospective study of histoplasmosis in patients infected with human immunodeficiency virus: Incidence, risk factors, and pathophysiology. Clin Infect Dis. 1997;24:1195-1203.
133. Kaplan JE, Masur H, Holmes KK; Infectious Disease Society of America. Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the US Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep. 2002;1 (RR-8):1-52.
134. Dewsnup DH, Galgiani JN, Graybill JR, et al. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis. Ann Intern Med. 1996;124: 305-310.
135. Mathew G, Smedema M, Wheat LJ, et al. Relapse of coccidioidomycosis despite immune reconstitution after fluconazole secondary prophylaxis in a patient with AIDS. Mycoses. 2003;46:42-44.
136. Koduri PR, Chundi V, Demarais P, et al. Reactive hemophagocytic syndrome: A new presentation of disseminated histoplasmosis in patients with AIDS. Clin Infect Dis. 1995;21:1463-1465.
137. De Lavaissiere M, Manceron V, Bouree P, et al. Reconstitution inflammatory syndrome related to histoplasmosis, with a hemophagocytic syndrome in HIV infection. J Infect. 2009;58:245-247.